Status of the ZUMA-3 trial of CAR T-cell product KTE-C19 for R/R ALL - 101793

Spotlight
Video

Status of the ZUMA-3 trial of CAR T-cell product KTE-C19 for R/R ALL

VJHemOnc has 1040 videos Subscribe Here

Loading........
Description: CAR T-cells for acute lymphoblastic leukemia (ALL) treatment are promising, with a number of different agents in development. Here, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the status of the Phase I/II ZUMA-3 trial of KTE-C19 for relapsed/refractory ALL. He also highlights his hopes for the study and the use of approaches such as minimal residual disease (MRD) measurement to guide therapy such as this. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.
Shared By : VJHemOnc
Posted on : 03/09/18
Added : 3 months ago